Determination of acute lung injury after repeated platelet transfusions

Corash, Laurence; Lin, Jin‐Sying; Sherman, Claire D.; Eiden, Joseph

doi:10.1182/blood-2010-06-293399

Cited by 36 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, acute respiratory distress syndrome (ARDS) was described in significantly more patients having received PI-PCs (5/328) than in those transfused with cPCs (0/327 [11]. A similar trend was seen following re-analysis of the data by independent experts (although not statistically significant anymore) [12]. Taking into consideration experimental data showing lung injury in lipopolysaccharide-treated mice following transfusion of UVB-irradiated PCs, whereas no lung-injury was observed following transfusion of non UV-irradiated PCs to otherwise identically treated mice [13], we still considered TRALI (transfusion-associated lung injury) in association with PI-PCs a potential risk.…”

Section: Introductionsupporting

confidence: 52%

“…In the Netherlands, bacterial screening is carried out on 100% of PCs by the BacT/ALERT 3D system. The claim that this screening proves to be successful in preventing the seriously contaminated PCs from entering the transfusion chain [12] is contested by reports from the USA, Canada, and Germany where the same screening system has been used. These countries describe cases of death resulting from bacterially contaminated PCs in up to 1:52,000 PC transfusions and conclude that bacterial screening may fail to identify over 50% of contaminated products, thus incurring the risk of septic transfusion reactions as a consequence of false-negative results in up to 1:26,000 transfusions [27,28,29,30,31].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland

Jutzi

Taleghani

Rueesch

et al. 2018

Transfus Med Hemother

View full text Add to dashboard Cite

Introduction: Bacterial contamination of platelet concentrates (PCs) has been identified as the most prevalent transfusion-associated infectious risk. To prevent PC-related septic transfusion reactions, the Intercept® pathogen inactivation procedure was introduced for all PCs in Switzerland in 2011. Methods: Based on numbers of transfused units and mandatorily reported adverse events with high imputability, we compare the risks associated with transfusion of conventional PCs (cPCs) and pathogen-inactivated PCs (PI-PCs). Results: From 2005 to 2011, a total of 158,502 cPCs have been issued in Switzerland, and 16 transfusion-transmitted bacterial infections (including 3 fatalities) were reported. This corresponds to a morbidity and mortality rate of ca. 1:9,900 and 1:52,800, respectively. From 2011 to 2016, a total of 205,574 PI-PCs have been issued, and no transfusion-transmitted bacterial infection was reported. Despite continuously increasing transfusion reaction rates per 1,000 RBC and plasma issued between 2008 and 2016, we observed reductions of 66% for life-threatening and fatal reactions and of 26% for all high-imputability transfusion reactions related to PI-PCs as compared to cPCs. No increased rates of bleeding or clinical observations of ineffectiveness of PI-PCs have been reported. After implementation of PI-PCs, the annual increase in platelet usage per 1,000 inhabitants decelerated. Discussion: Swiss hemovigilance data confirm a favorable safety profile of the nationwide introduced Intercept pathogen inactivation procedure and its reliable prevention of septic transfusion reactions and fatalities due to bacterially contaminated PCs.

show abstract

Section: Introductionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland

Jutzi

Taleghani

Rueesch

et al. 2018

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…However, a larger sample size would be required to definitively establish whether warming induced further degradation of PLT function. Also, as activated PLTs contribute to the pathogenesis of transfusion-related acute lung injury, [7][8][9][10] perhaps through the formation of neutrophil extracellular traps, 11 studying the impact of transit time through the warmer, flow rate and temperature on the activation status of the warmed PLTs will also be important in determining their safety.…”

Section: Discussionmentioning

confidence: 99%

Stored Platelet Functionality Is Not Decreased After Warming With a Fluid Warmer

König¹,

Yazer²,

Waters³

2014

Survey of Anesthesiology

View full text Add to dashboard Cite

show abstract

“…Gelderman and colleagues 1 reported a SCID mouse‐human platelet (PLT) transfusion model to test the hypothesis that UVB illumination of human PLT components (PCs) for pathogen inactivation (PI) potentiates acute lung injury (ALI). They extrapolated data from this model to conclude that UVA‐amotosalen PC potentiate ALI 2 based on a common mechanism for PLT damage. Significant questions arise from their study regarding applicability to human ALI.…”

mentioning

confidence: 99%

“…Finally, Gelderman and colleagues extrapolate their results with UVB in a small number of mice (n = 3 to 6) to the SPRINT trial with UVA‐PC in 645 patients 2 . They selectively cite data regarding the difference in the proportions of patients diagnosed with acute respiratory distress syndrome (a subset of ALI defined solely by the PaO 2 /F i O 2 ratio) and neglect data on lack of difference in the overall frequency of ALI between groups, or the longer time to mechanical ventilation with UVA‐PI, an objective measure of pulmonary failure 2 . Other data from the SPRINT trial showed no difference in the frequency of acute transfusion reactions, including TRALI, between groups 7 .…”

mentioning

confidence: 99%